News | January 22, 2014

BeneChill Receives Frost & Sullivan Award for Intranasal Cooling System for Therapeutic Hypothermia

BeneChill RhinoChill Therapeutic Hypothermia Cath Lab Intranasal Cooling System
January 22, 2014 — BeneChill Inc. received the 2014 Frost & Sullivan Award for Technology Innovation Leadership for its RhinoChill intranasal cooling system. 
 
BeneChill's RhinoChill is a nasopharyngeal device that can induce and sustain therapeutic hypothermia during active resuscitation after cardiac arrest. The system is noninvasive, time critical and can be used by nonmedical personnel to prevent brain damage associated with cardiac arrest.
 
RhinoChill is portable and battery-operated with a control unit, coolant bottle and a transnasal cooling catheter to facilitate use outside of hospital settings. The technology enables brain cooling close to the time of cerebral ischemic events, including in the absence of blood circulation. RhinoChill's technology initially targets brain cooling and then body cooling during cardiac arrest and after resuscitation.
 
The technology maintains therapeutic hypothermia brain temperatures by deploying two 10 cm long nasal catheter prongs that spray a mist of liquid proprietary coolant into the nasal cavity. The sprayed coolant evaporates on contact with the internal nares of the skull and facilitates rapid heat transfer. Lungs expel the coolant as inert and nontoxic gas.
 
RhinoChill’s operating input voltage is 10 to 18 V DC, and the control unit draws little current to enable battery operation. Its dimensions are 39 x 26 x 16 cm and it weighs approximately 5 to 9 kg. The system's components can connect in 30 to 60 seconds and can deploy immediately. RhinoChill features an auto shut off that is responsive to pressure in the nasal cavity beyond a threshold.
 
BeneChill plans to expand the technology to other fields such as traumatic brain injury, neuroradiology, neurosurgery and cardiac surgery.
 
Each year, Frost & Sullivan presents this award to the company that has demonstrated uniqueness in developing and leveraging new technologies, which significantly impacts both the functionality and the customer value of the new products and applications. The award lauds the high R&D spend towards innovation, its relevance to the industry and the positive impact on brand perception.
 
For more information: www.benechill.com, www.frost.com

Related Content

Videos | Cath Lab| January 04, 2018
Bernadette Speiser, BSN, MSN, CCRN, RCIS, a cardiac cath/EP nurse at Palo Alto Veterans Hospital, Palo Alto, Calif.,
FDA Initiates Class I Recall of Sterilmed Reprocessed Agilis Steerable Introducer Sheath
News | Cath Lab| January 04, 2018
The U.S. Food and Drug Administration (FDA) announced a Class I recall of Sterilmed’s Agilis Steerable Introducer...
The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA atherectomy system. Athar Ansari, M.D.

The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA system. 

Feature | Cath Lab| November 24, 2017 | Athar Ansari, M.D., FACC
As debates about the current state and future of healthcare rage in Congress, the media and healthcare settings acros
Videos | Cath Lab| November 08, 2017
Juan Granada, M.D., Cardiovascular Research Foundation president and chief executive officer, shares his insights on
Results of the ORBITA study found no difference in exercise time after six weeks in patients with stable angina who received percutaneous coronary intervention (PCI) versus a placebo treatment. TCT 2017
Feature | Cath Lab| November 06, 2017
November 6, 2017 – Results from ORBITA, a prospective multi-center randomized blinded placebo-controlled study, found
Culprit Lesion-Only PCI Improves Outcomes for Cardiogenic Shock Patients Compared to Multivessel PCI
News | Cath Lab| November 01, 2017
November 1, 2017 — Results from the prospective, randomized, multicenter CULPRIT-SHOCK trial found an initial strateg
Three-Year Quality of Life Improvements Similar for PCI and CABG in Left Main Disease
News | Cath Lab| October 30, 2017
October 30, 2017 — New study results from the EXCEL trial comparing the quality of life (QoL) of patients with left m
Corindus Evaluates Incorporating HeartFlow Technology With CorPath GRX System
Technology | Cath Lab| October 26, 2017
Corindus Vascular Robotics Inc. announced that it will incorporate the HeartFlow FFRct (fractional flow reserve-...
Shockwave Medical Announces $35 Million in New Financing
News | Cath Lab| October 24, 2017
October 24, 2017 — Shockwave Medical reported $35 million in new financing, an extension of the company’s previously
Overlay Init